This study, sponsored by Tianjin First Central Hospital, aims to evaluate the safety and efficacy of polyclonal antibodies in simultaneous pancreas-kidney transplant recipients. The market for immunosuppressive therapies in transplant patients is significant, with increasing demand for effective induction therapies. The comparative analysis of Grafalon and ATG may provide insights into optimal treatment regimens, potentially influencing prescribing practices and market share among competing products. Given the focus on diabetic nephropathy, this study aligns with the growing prevalence of diabetes-related complications, enhancing its commercial relevance. Stakeholders should monitor the outcomes closely, as they may impact future product positioning and market strategies.